Investors need to "live in the moment," but that's not always easy to do. Nevertheless, three stocks from various sectors are on my radar screen.
The first has the greatest risk: Keryx. Keryx, should perifosine receive the green light from the FDA, is going to go triple-percent meteoric. The stock is beginning its early move. Since 29 December 2011 at $2.38/share, the stock has rallied to today's high of $3.65/share. Given the stock was well-above $5/share in the last year, with perifosine's advancement, the stock should easily cross the $6/share mark.
While biotechs in this range can always be risky, there is a unique opportunity to go after triple digit percentage gains. As a tag-a-long stock to Keryx, investors may also want to take a look at AEterna Zentaris (NASDAQ:AEZS) that has also made a major move in its share price here on Friday.
Zynga is on fire and should stay on fire to well over $20/share. The revelation that Facebook (NASDAQ:FB) draws 12% of its revenues from Zynga is a staggering fact.
Early Friday morning I issued this alert:
On 16 December 2011, Zynga's IPO was listed at $10/share. The stock fell the first day to $9.50/share and then plunged to $8/share by 8 January 2012. But "times are a' changin'" with the announcement of Facebook's IPO filing.
I was 100% correct on this call, and I think it's going to continue. At last check, Zynga had climbed nearly 9% on today's trading.
Antares Pharma (AIS)
Antares has been on a monstrous run after falling to $1.67/share on 15 December 2011. Opinions seem to differ where the stock is heading next after reaching above $2.70/share. While technical indicators validate a momentary pull-back, this may be a case where the RSI may be giving investors a head-fake.
Antares is on the cusp of a major break north because the company is in the process of rolling out Anturol, its lead drug licensed to Watson (WPI) in North America for over-active bladder as well as Daewoong in South Korea. This is only the beginning as investors fully expect multiple partnerships including Europe, Japan, Australia, and South America.
What my analysis indicates is the stock is re-loading for the next leg up. I fully expect Antares to be over $3/share in the very near term and surging above $4/share before earnings in March 2012.
Disclosure: I am long AIS. Investors buy/sell at their own risk. 72 hours after publication, I am free to buy/sell, according to SA policy.